Declining cognitive health is a looming crisis in the US and worldwide. Early detection of impairment is essential to enabling research that can change the trajectory of these devastating diseases. Early detection is also crucial to altering the course of disease in participants and can aid clinical trials of new therapies. Current assessment methods include imaging, biomarker testing, and participant interviews. These methods are time consuming, invasive, and often prohibitively expensive.
DCT develops new tests of cognitive function to detect features that can identify and track presymptomatic change that: